FDA gives orphan-drug status to Cell Therapeutics brain cancer drug

10/2/2012 | American City Business Journals

The FDA granted orphan-drug designation to Cell Therapeutics' Opaxio, or paclitaxel poliglumex, to treat a malignant form of brain cancer. If the drug is approved, Cell Therapeutics will get seven years of market exclusivity, plus tax incentives and fee waivers.

View Full Article in:

American City Business Journals

Published in Briefs: